Fiber Tolerability in Children (FITIC)

Nestlé

Status: Completed

Conditions: Signs and Symptoms, Digestive

Treatments: Drug: Placebo (including Maltodextrin); Drug: PROMITOR® (including Maltodextrin)

Study type: Interventional

Funder types: Industry

Identifiers

NCT02519374

14.29. NRC

Details and patient eligibility

About

Assessment of the digestive tolerability of the PROMITOR® .

Full description

The trial will be multicenter, double-blind, placebo-controlled, randomized with a 4-arm parallel-design. The subjects wil be randomized to one of the four arms, i.e. four doses of investigational product balanced in maltodextrin, given at the doses of 6, 9 or 12 g (corresponding to 4, 6, or 8 g of fibers) twice a day with the meals of the morning and of the evening versus control (maltodextrin, no fibers) over one week of intake.

The total sample size is 40 healthy children from 8 to 12 years old, male and female.

Enrollment: 40 patients

Sex: All

Ages: 8 to 12 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy children,
• Aged between 8 and 12 years old included
• Acceptance of the taste of the product
• Having breakfast on daily basis
• Consent and/or assent received according to regulation
• Informed consent of one of the parents/guardians (for the study to be conducted in Switzerland, in respect with the Swiss regulation) or Informed consent of both parents/guardians (for the study to be conducted in France, in respect with the French regulation)
• Parents/guardians affiliated to a health insurance (only for the study to be conducted in France, in respect with the French regulation)

Exclusion criteria

• Specific food regimen
• Intolerability or food allergy
• Antibiotic or any medication impacting the gut transit during the 2 weeks before the study
• Chronic gastrointestinal disease
• Gastroenteritis in the 2 weeks preceding the study
• Constipation or diarrhea based on ROMEIII criteria (in average: more than 3 stools per day or less than 3 stools per week)
• Children and parents expected not to understand and perform the trial correctly (i.e.: troubles in learning and/or speaking)
• Child in a situation which, in the opinion of the principal investigator, could interfere with the optimal participation to the study or constitute a particular risk of non-compliance
• Having participated in another clinical trial for 1 month, or currently participating in a clinical trial
• Under legal protection or deprived from his rights following administrative or judicial decision (only for the study to be conducted in France, in respect with the French regulation)

Trial design

40 participants in 4 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

Placebo

Treatment:

Drug: Placebo (including Maltodextrin)

PROMITOR® dose 1

Active Comparator group

Description:

Investigational product dose 1

Treatment:

Drug: PROMITOR® (including Maltodextrin)

Drug: PROMITOR® (including Maltodextrin)

Drug: PROMITOR® (including Maltodextrin)

PROMITOR® dose 2

Active Comparator group

Description:

Investigational product dose 2

Treatment:

Drug: PROMITOR® (including Maltodextrin)

Drug: PROMITOR® (including Maltodextrin)

Drug: PROMITOR® (including Maltodextrin)

PROMITOR® dose 3

Active Comparator group

Description:

Investigational product dose 3

Treatment:

Drug: PROMITOR® (including Maltodextrin)

Drug: PROMITOR® (including Maltodextrin)

Drug: PROMITOR® (including Maltodextrin)